New KEYTRUDA ® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer

Dateline City: KENILWORTH, N.J. Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, in more than 15 types of cancer will be presented at the 52 nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3 – 7, 2016. Language: English Contact: Merck Media: Pamela Eisele, (267) 305-3558 Kim Hamilton, (908) 740-1863 or Investor: Teri Loxam, (908) 740-1986 Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news

Related Links:

Conclusions: Data highlight the value of molecular profiling in identifying populations with high unmet needs with potentially favorable response characteristics and accelerating development of novel therapies for these patients. Clin Cancer Res; 1-10. ©2018 AACR. PMID: 30442684 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
This article reviews the concept of immunotherapy in liver cancer with focus on nivolumab. Expert commentary: Immunotherapy in hepatocellular carcinoma provides a new treatment option for patients in advanced stages besides sorafenib and other newly approved tyrosine kinase inhibitors. More data concerning effectivity and choosing the right patients for immunotherapy is warranted in the future. PMID: 30304963 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Mutations in Tumor Protein P53 (p53) are expressed in a variety of human cancers such as cholangiocarcinoma, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, uterine cervical cancer, head and neck cancer, breast cancer, pancreatic cancer, and bladder cancer. The p53 protein is involved in determining whether DNA is repaired or the damaged cell undergoes apoptosis – thus acting as a tumor suppressor by regulating cell division. Mutations in the p53 protein can reduce or eliminate its tumor suppressor function or interfere with wild type p53 in...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
CONCLUSIONS: Subcutaneous ALT-803 produced the expected NK cell expansion and was well-tolerated with minimal cytokine toxicities and a strong local inflammatory reaction at injection sites in advanced cancer patients. These data, together with compelling evidence of synergy in preclinical and clinical studies, provide the rationale for combining ALT-803 with other anti-cancer agents. PMID: 30045932 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
We report a case of fatal myocarditis on anti–PD-L1 agent avelumab in combination with axitinib.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
For mesothelioma patients, immunotherapy is mostly available through clinical trials at this time. Immunotherapy is a relatively new way to treat cancer, and doctors still are learning who will respond best to these novel therapies. Newly released medical research has found men seem to respond better to immunotherapy than women. But this doesn’t mean immunotherapy is off the table for women with mesothelioma. You should learn all you can about how immunotherapy works, why it may or may not be right for you and how you can best prepare yourself if you decide an immunotherapy clinical trial is right for you. Thorough ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
1213Objectives: n 2011, the first immune checkpoint inhibitor monoclonal antibody was approved by FDA for treatment of advanced melanoma. Since then several new agents have been approved by FDA and increasingly been used as the first or second-line treatment for various neoplasms including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, and renal cell carcinoma. A subset of patients treated with these drugs demonstrates an atypical response pattern of initial progression followed by an eventual partial or complete response which was called pseudoprogression. These drugs ca...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Educational Exhibits Source Type: research
Authors: Dranitsaris G, Zhu X, Adunlin G, Vincent MD Abstract INTRODUCTION: After years of setback, cancer immunotherapy has begun to yield clinical dividends, which are changing the treatment landscape and offering cancer patients the potential for long-term survival, reduced treatment-related toxicity and improved quality-of-life. Using the immune system to treat cancer is known as 'Immuno-oncology' (IO) and agents are sub-classified by their ability to enhance anti-tumor response or to direct the immune system to attack cancer cells via tumor-associated antigens. Areas covered: Clinical trials have demonstrated ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Authors: Owczarek W, Słowińska M, Lesiak A, Ciążyńska M, Maciąg A, Paluchowska E, Marek-Józefowicz L, Czajkowski R Abstract Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including those of the head and neck area, non-small-cell lung cancer, and colorectal, cervical, prostate, breast, ovary, stomach, and pancreatic cancer. The EGFR inhibitors are used at present in the treatment of such cancers. Skin lesions that develop during and after cancer treatment may be due to specific cytostatics, molecular-targeted drugs, radiation therapy, complementary therapy, or th...
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
More News: Cancer | Cancer & Oncology | Head and Neck Cancer | Lung Cancer | Melanoma | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals | Skin Cancer